Research ArticleArticle
Open Access
Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis
Catherine Bakewell, Sibel Zehra Aydin, Veena K. Ranganath, Lihi Eder and Gurjit S. Kaeley
The Journal of Rheumatology November 2019, jrheum.190512; DOI: https://doi.org/10.3899/jrheum.190512
Catherine Bakewell
From the Intermountain Healthcare Medical Group, Salt Lake City, Utah, USA; University of Ottawa, Ottawa, Ontario, Canada; University of California, Los Angeles (UCLA), California, USA; Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA. This review article was sponsored by Novartis Pharmaceuticals Corp., which manufactures secukinumab. C. Bakewell has received consultancy fees from and/or served on speakers bureaus for AbbVie and Novartis Pharmaceuticals Corp. S.Z. Aydin has received honoraria from Novartis. V.K. Ranganath has served on the Data and Safety Monitoring Board for Amgen and has received grants for investigator-initiated studies from Mallinckrodt. L. Eder has received research or educational grants and/or consultancy fees from Novartis. G.S. Kaeley has received consultancy fees from Novartis. C. Bakewell, MD, Rheumatologist, Intermountain Healthcare Medical Group Salt Lake Clinic; S.Z. Aydin, MD, Associate Professor in Rheumatology, University of Ottawa, Ottawa Hospital Research Institute; V.K. Ranganath, MD, MS, Health Sciences Associate Clinical Professor, Division of Rheumatology, David Geffen School of Medicine at UCLA; L. Eder, MD, PhD, Assistant Professor of Medicine, Women’s College Research Institute, Women’s College Hospital, University of Toronto; G.S. Kaeley, MBBS, MRCP, RhMSUS, Professor, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine.Address correspondence to Dr. C. Bakewell, MD, RhMSUS, Intermountain Healthcare Medical Group, Salt Lake Clinic, 389 South 900 East, Salt Lake City, Utah 84102, USA. E-mail: bakewell@uw.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org.Accepted for publication October 23, 2019.
Sibel Zehra Aydin
From the Intermountain Healthcare Medical Group, Salt Lake City, Utah, USA; University of Ottawa, Ottawa, Ontario, Canada; University of California, Los Angeles (UCLA), California, USA; Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA. This review article was sponsored by Novartis Pharmaceuticals Corp., which manufactures secukinumab. C. Bakewell has received consultancy fees from and/or served on speakers bureaus for AbbVie and Novartis Pharmaceuticals Corp. S.Z. Aydin has received honoraria from Novartis. V.K. Ranganath has served on the Data and Safety Monitoring Board for Amgen and has received grants for investigator-initiated studies from Mallinckrodt. L. Eder has received research or educational grants and/or consultancy fees from Novartis. G.S. Kaeley has received consultancy fees from Novartis. C. Bakewell, MD, Rheumatologist, Intermountain Healthcare Medical Group Salt Lake Clinic; S.Z. Aydin, MD, Associate Professor in Rheumatology, University of Ottawa, Ottawa Hospital Research Institute; V.K. Ranganath, MD, MS, Health Sciences Associate Clinical Professor, Division of Rheumatology, David Geffen School of Medicine at UCLA; L. Eder, MD, PhD, Assistant Professor of Medicine, Women’s College Research Institute, Women’s College Hospital, University of Toronto; G.S. Kaeley, MBBS, MRCP, RhMSUS, Professor, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine.Address correspondence to Dr. C. Bakewell, MD, RhMSUS, Intermountain Healthcare Medical Group, Salt Lake Clinic, 389 South 900 East, Salt Lake City, Utah 84102, USA. E-mail: bakewell@uw.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org.Accepted for publication October 23, 2019.
Veena K. Ranganath
From the Intermountain Healthcare Medical Group, Salt Lake City, Utah, USA; University of Ottawa, Ottawa, Ontario, Canada; University of California, Los Angeles (UCLA), California, USA; Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA. This review article was sponsored by Novartis Pharmaceuticals Corp., which manufactures secukinumab. C. Bakewell has received consultancy fees from and/or served on speakers bureaus for AbbVie and Novartis Pharmaceuticals Corp. S.Z. Aydin has received honoraria from Novartis. V.K. Ranganath has served on the Data and Safety Monitoring Board for Amgen and has received grants for investigator-initiated studies from Mallinckrodt. L. Eder has received research or educational grants and/or consultancy fees from Novartis. G.S. Kaeley has received consultancy fees from Novartis. C. Bakewell, MD, Rheumatologist, Intermountain Healthcare Medical Group Salt Lake Clinic; S.Z. Aydin, MD, Associate Professor in Rheumatology, University of Ottawa, Ottawa Hospital Research Institute; V.K. Ranganath, MD, MS, Health Sciences Associate Clinical Professor, Division of Rheumatology, David Geffen School of Medicine at UCLA; L. Eder, MD, PhD, Assistant Professor of Medicine, Women’s College Research Institute, Women’s College Hospital, University of Toronto; G.S. Kaeley, MBBS, MRCP, RhMSUS, Professor, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine.Address correspondence to Dr. C. Bakewell, MD, RhMSUS, Intermountain Healthcare Medical Group, Salt Lake Clinic, 389 South 900 East, Salt Lake City, Utah 84102, USA. E-mail: bakewell@uw.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org.Accepted for publication October 23, 2019.
Lihi Eder
From the Intermountain Healthcare Medical Group, Salt Lake City, Utah, USA; University of Ottawa, Ottawa, Ontario, Canada; University of California, Los Angeles (UCLA), California, USA; Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA. This review article was sponsored by Novartis Pharmaceuticals Corp., which manufactures secukinumab. C. Bakewell has received consultancy fees from and/or served on speakers bureaus for AbbVie and Novartis Pharmaceuticals Corp. S.Z. Aydin has received honoraria from Novartis. V.K. Ranganath has served on the Data and Safety Monitoring Board for Amgen and has received grants for investigator-initiated studies from Mallinckrodt. L. Eder has received research or educational grants and/or consultancy fees from Novartis. G.S. Kaeley has received consultancy fees from Novartis. C. Bakewell, MD, Rheumatologist, Intermountain Healthcare Medical Group Salt Lake Clinic; S.Z. Aydin, MD, Associate Professor in Rheumatology, University of Ottawa, Ottawa Hospital Research Institute; V.K. Ranganath, MD, MS, Health Sciences Associate Clinical Professor, Division of Rheumatology, David Geffen School of Medicine at UCLA; L. Eder, MD, PhD, Assistant Professor of Medicine, Women’s College Research Institute, Women’s College Hospital, University of Toronto; G.S. Kaeley, MBBS, MRCP, RhMSUS, Professor, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine.Address correspondence to Dr. C. Bakewell, MD, RhMSUS, Intermountain Healthcare Medical Group, Salt Lake Clinic, 389 South 900 East, Salt Lake City, Utah 84102, USA. E-mail: bakewell@uw.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org.Accepted for publication October 23, 2019.
Gurjit S. Kaeley
From the Intermountain Healthcare Medical Group, Salt Lake City, Utah, USA; University of Ottawa, Ottawa, Ontario, Canada; University of California, Los Angeles (UCLA), California, USA; Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA. This review article was sponsored by Novartis Pharmaceuticals Corp., which manufactures secukinumab. C. Bakewell has received consultancy fees from and/or served on speakers bureaus for AbbVie and Novartis Pharmaceuticals Corp. S.Z. Aydin has received honoraria from Novartis. V.K. Ranganath has served on the Data and Safety Monitoring Board for Amgen and has received grants for investigator-initiated studies from Mallinckrodt. L. Eder has received research or educational grants and/or consultancy fees from Novartis. G.S. Kaeley has received consultancy fees from Novartis. C. Bakewell, MD, Rheumatologist, Intermountain Healthcare Medical Group Salt Lake Clinic; S.Z. Aydin, MD, Associate Professor in Rheumatology, University of Ottawa, Ottawa Hospital Research Institute; V.K. Ranganath, MD, MS, Health Sciences Associate Clinical Professor, Division of Rheumatology, David Geffen School of Medicine at UCLA; L. Eder, MD, PhD, Assistant Professor of Medicine, Women’s College Research Institute, Women’s College Hospital, University of Toronto; G.S. Kaeley, MBBS, MRCP, RhMSUS, Professor, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine.Address correspondence to Dr. C. Bakewell, MD, RhMSUS, Intermountain Healthcare Medical Group, Salt Lake Clinic, 389 South 900 East, Salt Lake City, Utah 84102, USA. E-mail: bakewell@uw.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org.Accepted for publication October 23, 2019.
Data supplements
Data Supplement
190512 Author Interview
Files in this Data Supplement:
190512 Video Abstract/Technique Demonstration
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis
Catherine Bakewell, Sibel Zehra Aydin, Veena K. Ranganath, Lihi Eder, Gurjit S. Kaeley
The Journal of Rheumatology Nov 2019, jrheum.190512; DOI: 10.3899/jrheum.190512